» Articles » PMID: 35388562

Late-Stage Modification of Aminoglycoside Antibiotics Overcomes Bacterial Resistance Mediated by APH(3') Kinases

Overview
Journal Chemistry
Specialty Chemistry
Date 2022 Apr 7
PMID 35388562
Authors
Affiliations
Soon will be listed here.
Abstract

The continuous emergence of antimicrobial resistance is causing a threat to patients infected by multidrug-resistant pathogens. In particular, the clinical use of aminoglycoside antibiotics, broad-spectrum antibacterials of last resort, is limited due to rising bacterial resistance. One of the major resistance mechanisms in Gram-positive and Gram-negative bacteria is phosphorylation of these amino sugars at the 3'-position by O-phosphotransferases [APH(3')s]. Structural alteration of these antibiotics at the 3'-position would be an obvious strategy to tackle this resistance mechanism. However, the access to such derivatives requires cumbersome multi-step synthesis, which is not appealing for pharma industry in this low-return-on-investment market. To overcome this obstacle and combat bacterial resistance mediated by APH(3')s, we introduce a novel regioselective modification of aminoglycosides in the 3'-position via palladium-catalyzed oxidation. To underline the effectiveness of our method for structural modification of aminoglycosides, we have developed two novel antibiotic candidates overcoming APH(3')s-mediated resistance employing only four synthetic steps.

Citing Articles

APH(3')-Ie, an aminoglycoside-modifying enzyme discovered in a rabbit-derived isolate.

Lin N, Sha Y, Zhang G, Song C, Zhang Y, Zhao J Front Cell Infect Microbiol. 2024; 14:1435123.

PMID: 39139766 PMC: 11320999. DOI: 10.3389/fcimb.2024.1435123.


Site-Selective Modification of (Oligo)Saccharides.

Witte M, Minnaard A ACS Catal. 2022; 12(19):12195-12205.

PMID: 36249871 PMC: 9552177. DOI: 10.1021/acscatal.2c03876.


Late-Stage Modification of Aminoglycoside Antibiotics Overcomes Bacterial Resistance Mediated by APH(3') Kinases.

Bastian A, Bastian M, Jager M, Loznik M, Warszawik E, Yang X Chemistry. 2022; 28(36):e202200883.

PMID: 35388562 PMC: 9321007. DOI: 10.1002/chem.202200883.

References
1.
Rajendran S, Rao Y, Karthikeyan V . Evaluation of target concentration intervention strategy of gentamicin therapy in a malnourished patient population of south India. Indian J Med Res. 2006; 122(6):511-7. View

2.
Zhang J, Chiang F, Wu L, Czyryca P, Li D, Chang C . Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. J Med Chem. 2008; 51(23):7563-73. PMC: 2664170. DOI: 10.1021/jm800997s. View

3.
Eljaaly K, Alharbi A, Alshehri S, Ortwine J, Pogue J . Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. Drugs. 2019; 79(3):243-269. DOI: 10.1007/s40265-019-1054-3. View

4.
Eisink N, Lohse J, Witte M, Minnaard A . Regioselective oxidation of unprotected 1,4 linked glucans. Org Biomol Chem. 2016; 14(21):4859-64. DOI: 10.1039/c6ob00608f. View

5.
Juhas M, Widlake E, Teo J, Huseby D, Tyrrell J, Polikanov Y . In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. J Antimicrob Chemother. 2019; 74(4):944-952. PMC: 6419615. DOI: 10.1093/jac/dky546. View